IN8BIO INC (INAB) Stock News

These stocks are moving in today's after hours session

Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.

Mentions: INFA MOVE DGLY PRTA ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Mentions: ABP HCTI EKSO AYTU ...

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights ...

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025...

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights ...

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a...

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Strong Durability of Remissions in High-Risk AML...

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients ...

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference...

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T...

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual...

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights...

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting...

IN8bio Announces Pricing of $12.4 Million Private Placement

IN8bio Announces Pricing of $12.4 Million Private Placement ...

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia ...

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference...

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

INAB Stock Earnings: IN8bio Misses EPS for Q2 2024

INAB stock results show that IN8bio missed analyst estimates for earnings per share the second quarter of 2024.

INAB Stock Earnings: IN8bio Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IN8bio (NASDAQ:INAB) just reported results for the second quarter of 2024.IN8bi...

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...

Gold Gains 1%; US Consumer Sentiment Falls In June

Mentions: GANX FOXO IRON SVMH ...